Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGN-3007 UltraCAR-T Cells in Advanced Hematologic and Solid Tumor Malignancies
NCT05694364Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of PRGN-3007 in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL) and 2 more (4 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Jan 2023; status: completed.
02
Drugs
PRGN-3007
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05694364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694364.